Video

Patricia Coyle from Stony Brook Medicine: Teri-PRO Trial shows Continued Benefits of Aubagio

Author(s):

When a medication is approved the data from that time can sometimes be of more value than the trials leading up to the approval. For Aubagio there was a recent study done looking at patient satisfaction and other issues following the approval.

When a medication is approved the data from that time can sometimes be of more value than the trials leading up to the approval. For Aubagio there was a recent study done looking at patient satisfaction and other issues following the approval.

Patricia K. Coyle, MD, from Stony Brook Medicine discussed the results of the Teri-PRO trial during the annual ECTRIMS conference in London. Coyle noted that the results focused more on patient reported results and issues than earlier trials. Through one year of research Coyle said there were definite benefits shown which was encouraging not only to the patients but also their providers as well.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.